Innovating medicines to
extend and improve the
lives of chronic
blood cancer patients

Transforming Oncology Drug Development Risk-Reward for Better Patient Outcome

Alethio Therapeutics is harnessing deep expertise to develop disease-modifying therapies that that could transform outcomes for patients with chronic blood cancers.

Our novel approach and pipeline are built on decades of pioneering research into the biology and treatment of myeloproliferative neoplasms (MPNs), a group of incurable and ultimately fatal blood cancers for which current treatments mainly offer symptomatic relief.

Our team brings together experts across discovery, development, biologics, clinical, and commercial for MPNs and is enabled by our proprietary discovery engine Artemis™, which combines advanced technologies underpinned by access to one of the world’s largest repositories of patient-derived MPN tissue.

Through Artemis, and with a relentless focus on patients, Alethio is translating cutting-edge biology into a new generation of disease-modifying therapies and redefining how MPNs are understood and how they are treated.

Addressing unmet need of MPN patients

Approximately 300,000 people are living with MPNs in the US alone. For people diagnosed with MPNs, life is often defined by pain, fatigue, and a limited life expectancy. Current treatments can ease symptoms, but don’t modify the disease’s course. Alethio is aiming to change that.

Artemis™

Artemis™ is Alethio’s proprietary discovery engine for MPNs.

Built to tackle the biological complexity of MPNs at its root, Artemis integrates unparalleled patient-derived data, advanced ‘omics, machine learning and disease-relevant organoid models to identify, validate and de-risk novel mutant drivers and therapeutic candidates positioned for clinical success.

Pipeline

Powered by Artemis™, Alethio is building a pipeline of novel biologic disease-modifying therapies for MPNs, focused on addressing significant unmet need.

Our lead programme, AT-01, represents a first-in-class therapeutic approach, focused on a novel target, aiming to shift treatment from symptom control toward true disease modification.

AT-02 targets mutant CALR driven disease, which represents ~30% of the MPN population.

Contact Us